Head to Head Analysis: Akcea Therapeutics (AKCA) vs. Its Competitors
Akcea Therapeutics (NASDAQ: AKCA) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Akcea Therapeutics to similar companies based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, risk, earnings and valuation.
Earnings and Valuation
This table compares Akcea Therapeutics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Akcea Therapeutics||N/A||-$83.21 million||-4.68|
|Akcea Therapeutics Competitors||$8.17 billion||$1.09 billion||127.80|
Akcea Therapeutics’ rivals have higher revenue and earnings than Akcea Therapeutics. Akcea Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current recommendations for Akcea Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Akcea Therapeutics Competitors||863||3776||6744||178||2.54|
Akcea Therapeutics presently has a consensus target price of $24.00, suggesting a potential upside of 30.22%. As a group, “Pharmaceuticals” companies have a potential upside of 21.55%. Given Akcea Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Akcea Therapeutics is more favorable than its rivals.
Insider & Institutional Ownership
19.2% of Akcea Therapeutics shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Akcea Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Akcea Therapeutics Competitors||-2,399.94%||-68.23%||-7.38%|
Akcea Therapeutics beats its rivals on 6 of the 11 factors compared.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company’s volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company’s clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.